GT Biopharma, Inc. (NASDAQ: GTBP) has announced that newly implemented artificial intelligence (AI) tools are accelerating its drug discovery and protein engineering efforts, with multiple new development candidates expected to enter pre-IND development in 2027. The company, a clinical-stage immuno-oncology firm focused on its proprietary natural killer (NK) cell engager platform, said the AI-driven approach is reducing reliance on trial-and-error experimentation and shortening timelines for identifying promising molecules.
AI Integration in Drug Design
According to the company's June 1, 2026 update, AI-guided sequence and structural analyses are now used to identify new tumor-targeting engagers and multi-domain proteins with favorable binding, stability, and developability profiles. This computational screening allows the team to prioritize molecules most likely to succeed before committing significant lab resources. In a field where the majority of early candidates fail, such in silico work saves both time and capital.
The AI tools also inform rational engineering of protein domains, linker design, and overall molecular architecture to enhance binding, support productive immune-synapse formation, and minimize structural liabilities that could affect potency or manufacturability. Downstream, AI-based structural modeling predicts surface exposure, steric compatibility, and assay performance, refining constructs before laboratory and animal studies.
Pipeline Progress and Expansion
GT Biopharma's clinical programs continue to advance alongside the AI integration. GTB-3650, targeting CD33-expressing blood cancers, is in Phase 1 trials, while GTB-5550, targeting B7-H3-expressing solid tumors, is also in Phase 1, with the first patient dosed in May 2026. The company anticipates that the AI-driven pipeline will expand beyond oncology into other indications, though specific new targets have not yet been disclosed.
“We are leveraging AI not as a marketing veneer but at the bench, in the actual design of our molecules,” a GT Biopharma representative stated. “This approach increases the likelihood that candidates show robust binding and functional activity before advancing, reducing wasted experiments and accelerating development.”
Industry Context
Other publicly traded companies exploring NK-cell therapies, immune engagers, or AI-driven drug discovery include Nkarta (NASDAQ: NKTX), Fate Therapeutics (NASDAQ: FATE), Compass Therapeutics (NASDAQ: CMPX), and Recursion (NASDAQ: RXRX). However, GT Biopharma emphasizes that each of these firms is distinct and none serves as a direct proxy for its own platform or pipeline.
The broader drug discovery landscape has long been characterized by slow, expensive trial and error. For small clinical-stage companies like GT Biopharma, every wasted experiment represents capital that is scarce. By screening computationally before committing to physical experiments, the company aims to reserve costly laboratory work for the most promising designs, potentially improving the efficiency of bringing new cancer therapies to patients.
